<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680099</article-id><article-id pub-id-type="doi">10.3390/v16121853</article-id><article-id pub-id-type="publisher-id">viruses-16-01853</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-7377-1652</contrib-id><name><surname>Gouissi Anguechia</surname><given-names>Davy-Hyacinthe</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af2-viruses-16-01853" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4187-683X</contrib-id><name><surname>Bouba</surname><given-names>Yagai</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af3-viruses-16-01853" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Semengue</surname><given-names>Ezechiel Ngoufack Jagni</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af4-viruses-16-01853" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2381-4299</contrib-id><name><surname>Ka&#x02019;e</surname><given-names>Aude Christelle</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Takou</surname><given-names>D&#x000e9;sir&#x000e9;</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af4-viruses-16-01853" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6749-1436</contrib-id><name><surname>Ambe Chenwi</surname><given-names>Collins</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af4-viruses-16-01853" ref-type="aff">4</xref><xref rid="af5-viruses-16-01853" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Beloumou</surname><given-names>Grace</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Nka</surname><given-names>Alex Durand</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Basseck Wome</surname><given-names>Ulrich Roland</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6228-1114</contrib-id><name><surname>Santoro</surname><given-names>Maria Mercedes</given-names></name><xref rid="af5-viruses-16-01853" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Ceccherini-Silberstein</surname><given-names>Francesca</given-names></name><xref rid="af5-viruses-16-01853" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Chatt&#x000e9;</surname><given-names>Adawaye</given-names></name><xref rid="af6-viruses-16-01853" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Montesano</surname><given-names>Carla</given-names></name><xref rid="af7-viruses-16-01853" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5353-5549</contrib-id><name><surname>Cappelli</surname><given-names>Giulia</given-names></name><xref rid="af8-viruses-16-01853" ref-type="aff">8</xref><xref rid="af9-viruses-16-01853" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Colizzi</surname><given-names>Vittorio</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af9-viruses-16-01853" ref-type="aff">9</xref><xref rid="af10-viruses-16-01853" ref-type="aff">10</xref><xref rid="af11-viruses-16-01853" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Ndjolo</surname><given-names>Alexis</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af2-viruses-16-01853" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Mbanya</surname><given-names>Dora</given-names></name><xref rid="af2-viruses-16-01853" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ndembi</surname><given-names>Nicaise</given-names></name><xref rid="af12-viruses-16-01853" ref-type="aff">12</xref><xref rid="af13-viruses-16-01853" ref-type="aff">13</xref><xref rid="c1-viruses-16-01853" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Perno</surname><given-names>Carlo-Federico</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af14-viruses-16-01853" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1501-2763</contrib-id><name><surname>Fokam</surname><given-names>Joseph</given-names></name><xref rid="af1-viruses-16-01853" ref-type="aff">1</xref><xref rid="af4-viruses-16-01853" ref-type="aff">4</xref><xref rid="af15-viruses-16-01853" ref-type="aff">15</xref><xref rid="af16-viruses-16-01853" ref-type="aff">16</xref><xref rid="c1-viruses-16-01853" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Poulin Porter</surname><given-names>Danielle</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Vermillion</surname><given-names>Meghan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01853"><label>1</label>Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaound&#x000e9; P.O. Box 3077, Cameroon; <email>davygouissi@gmail.com</email> (D.-H.G.A.); <email>romeobouba@yahoo.fr</email> (Y.B.); <email>ezechiel.semengue@gmail.com</email> (E.N.J.S.); <email>kae.audechristelle@gmail.com</email> (A.C.K.); <email>dtakou@yahoo.com</email> (D.T.); <email>collinschen@yahoo.co.uk</email> (C.A.C.); <email>graceangong12@yahoo.fr</email> (G.B.); <email>nkaalexdurand@yahoo.com</email> (A.D.N.); <email>freedywilliam@gmail.com</email> (U.R.B.W.); <email>colizzi@bio.uniroma2.it</email> (V.C.); <email>andjolo@yahoo.com</email> (A.N.); <email>carlofederico.perno@opbg.net</email> (C.-F.P.)</aff><aff id="af2-viruses-16-01853"><label>2</label>Faculty of Medicine and Biomedical Sciences, University of Yaound&#x000e9; I, Yaound&#x000e9; P.O. Box 337, Cameroon; <email>dmbanya1@yahoo.co.uk</email></aff><aff id="af3-viruses-16-01853"><label>3</label>Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy</aff><aff id="af4-viruses-16-01853"><label>4</label>National HIV Drug Resistance Working Group, Yaound&#x000e9; P.O. Box 1459, Cameroon</aff><aff id="af5-viruses-16-01853"><label>5</label>Department of Experimental Medicine, University of Rome &#x0201c;Tor Vergata&#x0201d;, 00133 Rome, Italy; <email>santormaria@gmail.com</email> (M.M.S.); <email>ceccherini@med.uniroma2.it</email> (F.C.-S.)</aff><aff id="af6-viruses-16-01853"><label>6</label>Project Management Unit, Ministry of Health, N&#x02019;djamena P.O. Box 548, Chad; <email>cadawaye@yahoo.fr</email></aff><aff id="af7-viruses-16-01853"><label>7</label>Department of Biology, University of Rome &#x0201c;Tor Vergata&#x0201d;, 00133 Rome, Italy; <email>montesan@uniroma2.it</email></aff><aff id="af8-viruses-16-01853"><label>8</label>National Research Council, 00185 Rome, Italy; <email>giulia.cappelli@cnr.it</email></aff><aff id="af9-viruses-16-01853"><label>9</label>LAGET, Centre Hospitalo-Universitaire (CHU), N&#x02019;djamena P.O. Box 456, Chad</aff><aff id="af10-viruses-16-01853"><label>10</label>EUROBIOPARK and UNSECO Board for Biotechnology, University of Rome &#x0201c;Tor Vergata&#x0201d;, 00133 Rome, Italy</aff><aff id="af11-viruses-16-01853"><label>11</label>Faculty of Sciences and Technology, Evangelical University of Cameroon, Bandjoun P.O. Box 127, Cameroon</aff><aff id="af12-viruses-16-01853"><label>12</label>Africa Centres for Disease Control and Prevention, Addis Ababa P.O. Box 3243, Ethiopia</aff><aff id="af13-viruses-16-01853"><label>13</label>Institute of Human Virology, Baltimore, MD 21201, USA</aff><aff id="af14-viruses-16-01853"><label>14</label>Bambino Ges&#x000f9; Children Hospital, IRCCS, 00146 Rome, Italy</aff><aff id="af15-viruses-16-01853"><label>15</label>Faculty of Health Sciences, University of Buea, Buea P.O. Box 63, Cameroon</aff><aff id="af16-viruses-16-01853"><label>16</label>Central Technical Group, National AIDS Control Committee, Yaound&#x000e9; P.O. Box 1459, Cameroon</aff><author-notes><corresp id="c1-viruses-16-01853"><label>*</label>Correspondence: <email>nicaisen@africa-union.org</email> (N.N.); <email>josephfokam@gmail.com</email> (J.F.)</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1853</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Dual therapies (DT) combining integrase strand transfer inhibitors (INSTIs) with second-generation non-nucleoside reverse transcriptase inhibitors (2nd-Gen-NNRTIs) offer new possibilities for HIV treatment to improve adherence. However, drug resistance associated mutations (RAMs) to prior antiretrovirals may jeopardize the efficacy of DT. We herein describe the predicted efficacy of DT combining INSTIs + 2nd-Gen-NNRTI following treatment failure among Cameroonian patients. We genotyped the HIV-1 <italic toggle="yes">pol</italic> gene using Sanger sequencing and assessed acquired RAMs to NNRTIs and INSTIs in patients failing treatment from March 2019 to December 2023. Drug susceptibility was interpreted using Stanford HIVdb v9.5, and statistical analyses were performed using SPSS v22. Of 130 successfully genotyped participants (median age (IQR): 38 (27&#x02013;46) years; 59.2% female), 92.3% had RAMs to NNRTIs and 1.5% to INSTIs. Prevailing RAMs were Y181C (32.3%) among NNRTIs and R263K (0.7%) among INSTIs. Among 2nd-Gen-NNRTIs, etravirine, doravirine and rilpivirine had 43.85%, 41.54% and 38.46% genotypic sensitivity, respectively. Among INSTIs, we found 97.69% efficacy for dolutegravir/bictegravir, 96.15% for cabotegravir and 92.31% for elvitegravir/raltegravir. The overall predictive efficacy of DT was lower among participants who failed 1st-Gen-NNRTI (<italic toggle="yes">p</italic> &#x0003c; 0.001); with etravirine + dolutegravir/bictegravir combination showing the highest score (43.8%). Conclusively, DT combining INSTIs + 2nd-Gen-NNRTIs might be suboptimal in the context of previous ART failure, especially with NNRTI-based treatment in low- and middle-income countries. The general data clearly indicate that without resistance testing, it is nearly impossible to use long-acting dual therapies in previously failing patients.</p></abstract><kwd-group><kwd>HIV-1</kwd><kwd>dual therapies</kwd><kwd>predictive efficacy</kwd><kwd>non-nucleosides reverse transcriptase inhibitors</kwd><kwd>integrase strand transfer inhibitor</kwd><kwd>Cameroon</kwd></kwd-group><funding-group><award-group><funding-source>Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB)</funding-source></award-group><award-group><funding-source>Collaborative Initiative for Paediatric HIV Education and Research</funding-source><award-id>CIPHER-ADOLA-2023</award-id></award-group><funding-statement>This work was financially and technically supported by the Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB), and partly supported by the grant received from the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER-ADOLA-2023).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01853"><title>1. Introduction</title><p>Antiretroviral therapy (ART) has significantly reduced AIDS-related morbidity and mortality by slowing down HIV replication to the point where the viral load (VL) in the peripheral blood is undetectable [<xref rid="B1-viruses-16-01853" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01853" ref-type="bibr">2</xref>]. To date, triple therapy (TT) regimens remain the &#x0201c;gold standard&#x0201d; for HIV treatment in resource-limited settings, whereas dual therapies (DT) are among the first choices in the majority of Western guidelines. With this ART strategy, the number of new HIV infections has fallen by more than 60% since the peak in 1995&#x02013;1997 [<xref rid="B1-viruses-16-01853" ref-type="bibr">1</xref>]. However, there are still 39 million people living with HIV (PLHIV) globally (with Sub-Saharan Africa accounting for more than 70%), and 1.3 million people newly infected in 2022 [<xref rid="B1-viruses-16-01853" ref-type="bibr">1</xref>]. In 2022, in Cameroon, 480,228 people were living with HIV, with 9898 new HIV infections and 10,198 people dying of an AIDS-related illness [<xref rid="B3-viruses-16-01853" ref-type="bibr">3</xref>]. Despite efforts to move towards remission or even lasting eradication of HIV, lifelong ART regimens appear to be the only option for patients to restore and maintain good health [<xref rid="B4-viruses-16-01853" ref-type="bibr">4</xref>]. However, in the context of lifelong ART, there is a growing need for treatment simplification strategies to minimize the cumulative toxicity of drug exposure [<xref rid="B5-viruses-16-01853" ref-type="bibr">5</xref>], while also improving patients&#x02019; adherence to their ART. For more than two decades, in low- and middle-income countries (LMICs) like Cameroon, the backbone for all ART-regimen lines (first, second and third) has been the combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) such as tenofovir disoproxil fumarate (TDF), lamivudine (3TC), zidovudine (AZT) or abacavir (ABC) [<xref rid="B6-viruses-16-01853" ref-type="bibr">6</xref>]. Of note, some of these NRTIs have been associated with bone, renal and metabolic toxicities that are superimposed on the comorbidities associated with aging [<xref rid="B7-viruses-16-01853" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01853" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01853" ref-type="bibr">9</xref>] and can lead to significant problems, including long-term toxicity and adherence [<xref rid="B10-viruses-16-01853" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01853" ref-type="bibr">11</xref>]. Therefore, managing PLWH with multimorbidity and polypharmacy remains a significant challenge for clinicians and requires the implementation of new ART strategies like DT. DT combining integrase inhibitors and non-NRTIs (NNRTIs) represents a promising regimen in aging HIV-infected individuals with long exposure to nucleoside analogues and protease inhibitors (PIs) [<xref rid="B5-viruses-16-01853" ref-type="bibr">5</xref>]. Etravirine (ETR), rilpivirine (RPV) and doravirine (DOR), the second-generation NNRTIs, are three recently approved NNRTIs by the U.S. FDA (United States Food and Drug Administration) that can be effective against HIV variants resistant to first-generation NNRTIs [<xref rid="B12-viruses-16-01853" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01853" ref-type="bibr">13</xref>,<xref rid="B14-viruses-16-01853" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01853" ref-type="bibr">15</xref>]. Integrase strand transfer inhibitors (INSTIs), i.e., raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), bictegravir (BIC) and cabotegravir (CAB), are highly potent, with limited toxicity, and have become the cornerstone of modern ART worldwide [<xref rid="B16-viruses-16-01853" ref-type="bibr">16</xref>]. Therefore, to control HIV viral replication, two of these new drugs (INSTIs and 2nd-Gen-NNRTI) are sufficient.</p><p>In many studies, these drugs, combined in DT, have shown promising results for ART-experienced patients. For example, DT combining raltegravir with etravirine (ANRS 163 ETRAL trial) [<xref rid="B17-viruses-16-01853" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01853" ref-type="bibr">18</xref>], DTG with RPV (SWORD-1 and SWORD-2 studies) [<xref rid="B19-viruses-16-01853" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01853" ref-type="bibr">20</xref>] and long-acting CAB plus RPV (FLAIR and ATLAS clinical trials) [<xref rid="B21-viruses-16-01853" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01853" ref-type="bibr">22</xref>] maintained a high level of viral suppression over 96 weeks in long-term, experienced HIV-infected individuals. Among INSTIs with 2nd-Gen-NNRTI combinations studied, only the long-acting injectable (LAI) RPV + CAB and RPV + DTG combinations have been validated and approved by the U.S. FDA [<xref rid="B12-viruses-16-01853" ref-type="bibr">12</xref>].</p><p>In general, DT is a recommended option for individualized treatment of HIV-1 infection in the Western world, with HIV viral load &#x0003c;50 copies/mL on oral ART, no history of virological failure and no history of NNRTIs drug resistance mutations (RAM). In particular, long-acting therapies are now considered of paramount importance for a number of reasons, such as increasing efficacy, reducing the negative effects of lack of adherence and limiting stigma. For all these reasons, long-acting therapies are seen as a relevant option in low- and middle-income countries, especially in Africa. However, in countries, like Cameroon, there is a large proportion of people with previous exposure to/experiencing failure with NNRTI-containing regimens (and archived NNRTI resistance) [<xref rid="B23-viruses-16-01853" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01853" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01853" ref-type="bibr">25</xref>] and high viral subtype diversity [<xref rid="B26-viruses-16-01853" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01853" ref-type="bibr">27</xref>]. HIV-infected populations generally have limited access to virological monitoring and/or genotypic resistance testing, which is likely to lead to an accumulation of NNRTI resistance [<xref rid="B23-viruses-16-01853" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01853" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01853" ref-type="bibr">25</xref>]. For all these reasons, the potential relevance of this new approach needs to be considered in practice in light of the overall rate of failures and resistance to INSTI and/or NNRTI, in order to evaluate which patients&#x02014;how many are they&#x02014;have real chances to benefit from this approach.</p><p>Therefore, the aim of this study was to explore the potential targets eligible for DT among patients experiencing virological failure, in order to optimize the use of DT in our context. Using HIV genotypic resistance testing, we assessed the predictive efficacy of dual ART combinations (approved, in development, not reported to be in development) based on second-generation INSTI and 2nd-Gen-NNRTI among PLHIV failing their ART in Cameroon. Specifically, we analysed genetic variations in HIV-1 <italic toggle="yes">pol</italic> sequences to describe the predicted efficacy of DT combining 2nd-INSTIs + 2nd-Gen-NNRTI following treatment failure in Cameroon.</p></sec><sec id="sec2-viruses-16-01853"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01853"><title>2.1. Study Population and Design</title><p>A laboratory-based cross-sectional study was carried out from March 2019 to December 2023, among PLHIV failing their ART (viral load &#x02265; 1000 HIV-1 RNA copies/mL following an unsuppressed VL and adherence support) who were received for genotypic resistance testing at the Virology Laboratory of the &#x0201c;Chantal BIYA&#x0201d; International Reference Centre for research on HIV/AIDS prevention and management (CIRCB) in Yaound&#x000e9;-Cameroon. Available demographic data, including age and gender, as well as clinical data such as ART regimen, duration on ART and viremia, were collected from clinical files.</p><p>The virology laboratory of CIRCB is a national reference laboratory for HIV-1 genotypic drug resistance testing and a reference for surveillance of HIV drug resistance at the country level (<uri xlink:href="https://www.circb.cm/btc_circb/web/">https://www.circb.cm/btc_circb/web/</uri>, accessed on 2 April 2024).</p></sec><sec id="sec2dot2-viruses-16-01853"><title>2.2. Laboratory Methods</title><sec id="sec2dot2dot1-viruses-16-01853"><title>2.2.1. Sanger Sequencing Procedure</title><p>Viral RNA was extracted from plasma samples using the QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany). HIV-1 amplification and sequencing of the approximately 1200 base pair (bp) protease and reverse transcriptase regions were performed using a previously described in-house RT-PR genotyping assay [<xref rid="B28-viruses-16-01853" ref-type="bibr">28</xref>]. HIV-1 integrase (864 bp) was amplified and sequenced using a highly sensitive integrase genotyping assay [<xref rid="B29-viruses-16-01853" ref-type="bibr">29</xref>]. Capillary electrophoresis was carried out using an Applied Biosystems 3500 genetic analyser (Applied Biosystems, Waltham, MA, USA).</p></sec><sec id="sec2dot2dot2-viruses-16-01853"><title>2.2.2. Bioinformatics Analysis</title><p>Sequences were assembled and edited using RECall (CDC, Atlanta, GA, USA). Sequence analysis for interpretation was performed using the Stanford HIV database algorithm v9.5 (<uri xlink:href="https://hivdb.stanford.edu/page/algorithm-updates/">https://hivdb.stanford.edu/page/algorithm-updates/</uri>, accessed on 2 May 2024). All generated sequences were aligned using BioEdit version 7.2.6 (Tom Hall, Raleigh, NC, USA) and compared to reference sequences from the Los Alamos database (<uri xlink:href="https://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html">https://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html</uri>, accessed on 2 May 2023); HIV subtypes were identified using the Nextclade v3.8.2 sequence analysis web app (<uri xlink:href="https://clades.nextstrain.org/">https://clades.nextstrain.org/</uri>, accessed on 14 June 2023).</p></sec></sec><sec id="sec2dot3-viruses-16-01853"><title>2.3. Analyses of Potential Drug Susceptibilities</title><p>The potential efficacy of dual combinations involving 2nd-Gen-NNRTIs with INSTIs was estimated based on the genotypic susceptibility prediction provided by the Stanford HIV database algorithm v9.5 (<uri xlink:href="https://hivdb.stanford.edu/hivdb/by-patterns/">https://hivdb.stanford.edu/hivdb/by-patterns/</uri>, accessed on 2 May 2024). INSTIs and NNRTIs susceptibilities were interpreted using the genotypic scoring system for drug susceptibility with the following penalty scores: &#x02265;60: high resistance; 15&#x02013;59: intermediate resistance; &#x0003c;15: susceptible.</p></sec><sec id="sec2dot4-viruses-16-01853"><title>2.4. Statistical Analysis</title><p>Qualitative variables were presented as numbers and percentages, while quantitative variables were presented as median and interquartile range (IQR). For the statistical tests, comparisons were performed using the Chi-square test (&#x003c7;<sup>2</sup>) or Fisher&#x02019;s exact test, wherever appropriate for categorical variables, using the Statistical Package for Social Science (SPSS) software version 22. The statistical significance level was set at <italic toggle="yes">p</italic> &#x0003c; 0.05 for all tests.</p></sec><sec id="sec2dot5-viruses-16-01853"><title>2.5. Ethical Considerations</title><p>Administrative authorization was obtained from CIRCB (reference N&#x000b0; 1855/22, issued on 15 September 2022), and ethical clearance was obtained from the Institutional Ethics Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaound&#x000e9; I (reference N&#x000b0; 0043/UY1/FMSB/VDRC/DAASR/CSD, approved on 6 February 2023). Unique identifiers and a protected database were used for confidentiality purposes and privacy in data management.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01853"><title>3. Results</title><sec id="sec3dot1-viruses-16-01853"><title>3.1. Characteristics of the Study Population</title><p>A total of 130 participants were included in this study. Participants were predominantly female (59.2%), and the median (interquartile range IQR) age was 38 (27&#x02013;46) years. The median (IQR) ART duration was 84 (42&#x02013;144) months; 52 (40.0%) participants were failing regimens based on 2 NRTIs + 1 NNRTI, 66 (50.8%) based on 2 NRTIs + 1 ritonavir-boosted protease inhibitor (PI/r) and 12 (9.2%) based on 2 NRTIs + 1 INSTI. Overall, 123 participants (94.6%) had a current/previous exposure to NNRTI-containing regimens, versus only 9.2% exposure to INSTI-based regimens.</p><p>The sociodemographic and clinical data of the participants are shown in <xref rid="viruses-16-01853-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3dot2-viruses-16-01853"><title>3.2. Subtype Analysis</title><p>Among the 130 PR/RT sequences, phylogenetic analysis (<xref rid="viruses-16-01853-f001" ref-type="fig">Figure 1</xref>) revealed that CRF02_AG (60.0%; 78/130) was the most prevalent HIV-1 strain, followed by the subtypes G (6.9%), CRF22_01A1 (6.9%), D (5.8%), F2 (4.8%), CRF11_cpx (3.2%) and other HIV-1 subtypes such as CRF18_cpx (2.3%), CRF13_cpx (1.5%), CRF37_cpx (1.5%), CRF01_AE (1.5%), A1 (0.7%), A3 (0.7%), B (0.7%), C (0.7%), CRF06_cpx (0.7%), CRF09_cpx (0.7%), CRF26_A5U (0.7%) and CRF36_cpx (0.7%) were also detected, but with a low frequency.</p></sec><sec id="sec3dot3-viruses-16-01853"><title>3.3. Genotypic Profiles of the Study Population at Failure</title><p>Concerning RAMs to NNRTIs, 120 (92.3%) harboured NNRTI resistance; 96.6% (119/123) in the NNRTI-exposed group and 14.2 % (1/7) in the NNRTI-non-exposed group; <italic toggle="yes">p</italic> &#x0003c; 0.01).</p><p>Concerning NNRTIs and specifically 2nd-Gen-NNRTIs (i.e., DOR, ETR and RPV), prevailing RAMs were Y181C (32.3%), V179L (13.8%), K101PE (10.7%) and H221Y (6.9%) (<xref rid="viruses-16-01853-t002" ref-type="table">Table 2</xref>). Drug susceptibility assessment revealed that 58.5% (76/130) of patients had intermediate to high-level resistance to DOR, 56.2% (73/130) to ETR and 61.5% (80/130) to RPV (see <xref rid="viruses-16-01853-t003" ref-type="table">Table 3</xref>). Among participants who switched to NNRTI-based regimens (N = 78), only 7.7% (6/78) had no NNRTI-RAMs. The median ART duration (IQR; years) after switching was not significant between patients with NNRTI-RAMs and patients without NNRTI-RAMS (3.5 (2.0&#x02013;6.0) vs. 6 (5.0&#x02013;7.5), respectively; <italic toggle="yes">p</italic> = 0.1).</p><p>Regarding RAMs to INSTI, two (1.54%) participants harboured INSTI-RAMs. Both cases were found in INSTI-exposed patients (2/12 (16.6%)), and no resistance was observed in the INSTI-non-exposed group. Among participants harbouring major RAMs to INSTIs, we found specifically E138K (1/130), G140A (1/130), Q148R (1/130), R263K (1/130), and S147G (1/130) (<xref rid="viruses-16-01853-t002" ref-type="table">Table 2</xref>). Some participants harboured a polymorphic INSTI-selected mutation such as T97A (18.5%) and L74I (22.3%).</p><p>Stanford genotypic susceptibility revealed that 3.9% (5/130) of participants harboured an intermediate or high level of resistance to CAB and 2.3% (3/130) to DTG/BIC (see <xref rid="viruses-16-01853-t003" ref-type="table">Table 3</xref>).</p><p>Following genotyping, 9/130 (6.8%) of participants did not harbour any RAMs to NNRTIs or INSTIs.</p></sec><sec id="sec3dot4-viruses-16-01853"><title>3.4. Predicted Efficacy of Dual Therapy Combining INSTIs and 2nd-Gen-NNRTI</title><p><xref rid="viruses-16-01853-f002" ref-type="fig">Figure 2</xref> summarizes the predictive efficacy according to the Stanford database (scored as &#x0003c;15) of all possible DT combining 2nd-Gen-NNRTIs combined with INSTIs. Overall, the dual regimen with highest predictive efficacy was ETR + INSTIs, whereas the lowest was RPV + INSTIs.</p></sec><sec id="sec3dot5-viruses-16-01853"><title>3.5. Determinants of INSTIs + NNRTI Efficacies in Dual Therapies</title><p>Globally, the statistics revealed that age, duration of treatment and viral subtype were not associated with the efficacy of various potential DT. However, the potential efficacy appeared to be lower (<italic toggle="yes">p</italic> &#x0003c; 0.05 in all cases) among participants who previously failed an NNRTI-based protocol and those harbouring RAMs (<xref rid="viruses-16-01853-f003" ref-type="fig">Figure 3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01853"><title>4. Discussion</title><p>Simplified single-pill-a-day tritherapy has radically changed patients&#x02019; lives. Currently, there are further strategies aimed at reducing the number of drugs or the frequency with which they are taken, with a good safety profile. INSTIs and 2nd-Gen-NNRTIs are an HIV ART that has demonstrated efficacy in treatment-naive, treatment-experienced and drug-resistant subjects [<xref rid="B14-viruses-16-01853" ref-type="bibr">14</xref>,<xref rid="B30-viruses-16-01853" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01853" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01853" ref-type="bibr">32</xref>]. Studies of INSTIs in combination with 2nd-Gen-NNRTIs provided the most definitive evidence supporting a role for dual therapy [<xref rid="B33-viruses-16-01853" ref-type="bibr">33</xref>]. This study evaluated the predictive efficacy of co-administration of INSTIs with 2nd-Gen-NNRTI-based antiretroviral strategies to determine whether these new regimens can be considered suitable alternatives to standard regimens as replacement therapy for patients in virological failure.</p><p>In the reverse transcriptase (RT) region of HIV-1 pol, analysis showed a high prevalence of NNRTI-RAMs, including Y181C, Y188C and K101PE, which significantly reduce the efficacy of 2nd-Gen-NNRTIs. This high rate of NNRTI-RAMs can be explained by the fact that about 95% had failed first-generation NNRTIs (EFV and NVP) due to their low genetic barrier to resistance [<xref rid="B23-viruses-16-01853" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01853" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01853" ref-type="bibr">25</xref>].</p><p>However, 43.85%, 41.54% and 38.46% of the study population remained susceptible to etravirine, doravirine and rilpivirine, respectively. In fact, the previous reported mutations, although frequent, do not necessarily affect the efficacy of 2nd-Gen-NNRTIs at the same levels. For example, Y181C does not affect DOR [<xref rid="B34-viruses-16-01853" ref-type="bibr">34</xref>].</p><p>Concerning integrase inhibitors, major INSTI-RAMs, such as R263K, S147G, G140A and Q148R, were very rare (&#x0003c;2%). Our study differs from that of Ndashimye et al. (2020) in Uganda, who observed a higher rate of INSTI-RAMs in 47% of patients [<xref rid="B35-viruses-16-01853" ref-type="bibr">35</xref>]. This disparity could be explained by variations in patient selection and inclusion criteria. In fact, this Ugandan study was carried out in 52 patients failing a RAL-based regimen. Most samples contained minor mutations such as L74I (29/130), which can modulate susceptibility without causing complete resistance [<xref rid="B36-viruses-16-01853" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01853" ref-type="bibr">37</xref>]. One factor that appeared initially to be associated with virologic failure to long-acting CAB + RPV was the L74I integrase polymorphism; however, its role in virologic outcome was unclear [<xref rid="B22-viruses-16-01853" ref-type="bibr">22</xref>,<xref rid="B38-viruses-16-01853" ref-type="bibr">38</xref>]. According to the Stanford HIVdb algorithm, the predictive efficacy (96.2%) of CAB was lower than that of BIC and DTG (97.7%). This is because DTG and BIC are second-generation INSTIs with a higher genetic barrier to resistance than cabotegravir [<xref rid="B39-viruses-16-01853" ref-type="bibr">39</xref>]. Despite the small proportion of patients exposed to INSTIs, these results suggest that INSTIs such as dolutegravir remain a viable option for the management of HIV infection in our context.</p><p>Depending on certain factors, this relatively favourable genotypic resistance profile justifies the use of this DT combining INSTIs/2nd-Gen-NNRTIs in the context of virological failure. Overall, the different combinations of INSTIs/2nd-Gen-NNRTIs proved effective, regardless of age, duration of treatment or viral subtype. However, participants who have failed on first-generation NNRTI-based regimens (EFV or NVP) were less sensitive to DT INSTI/NNRTI-based DT compared to those who have failed on PI/r or INSTIs. In fact, virological failure under EFV/NVP-based regimens is often accompanied by the accumulation of NNRTI-RAMs in the HIV genome, which confer cross-resistance to 2nd-Gen-NNRTIs (ETR, DOR, RPV) [<xref rid="B40-viruses-16-01853" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01853" ref-type="bibr">41</xref>]. Indeed, NNRTIs are known to have a low genetic barrier (a single mutation such as M230L is enough to cause resistance to all drugs in the class) [<xref rid="B42-viruses-16-01853" ref-type="bibr">42</xref>]. On the other hand, participants in virological failure without mutations to any of the NNRTIs or INSTIs all (100%) showed total efficacy with DT INSTI/2nd-Gen-NNRTIs, underlining the importance of genotypic resistance testing to aid the selection of potential candidates for DT despite exposure to previous ART regimens.</p><p>Among the DT- INSTI/2nd-Gen-NNRTI combinations approved by the FDA, only the efficacy of the long-acting injectable combination (LAI) CAB + RPV has been evaluated in Africa through the CARES randomised trial (in Uganda, Kenya and South Africa) [<xref rid="B43-viruses-16-01853" ref-type="bibr">43</xref>]. This clinical trial included participants with viremia below 50 copies/mL, who had never failed therapy. In this study, long-acting CAB + RPV therapy had non-inferior efficacy compared with oral therapy, with a good safety profile, and could be considered for African treatment programs [<xref rid="B43-viruses-16-01853" ref-type="bibr">43</xref>]. In our study, genotypic analysis predicts the efficacy of CAB/RPV in 36.2% (47/130) of participants after virological failure. This low rate of genotypic susceptibility is mainly due to the high rate of NNRTI-RAMs in our study population. In fact, certain specific mutations present in patients undergoing treatment with efavirenz or nevirapine may also reduce the efficacy of RPV [<xref rid="B44-viruses-16-01853" ref-type="bibr">44</xref>]. This high prevalence of NNRTI resistance has previously been described in several studies in our context [<xref rid="B25-viruses-16-01853" ref-type="bibr">25</xref>,<xref rid="B41-viruses-16-01853" ref-type="bibr">41</xref>]. Consequently, the efficacy of a long-acting injectable protocol may be suboptimal in our context due to the phenomenon of cross-resistance to RPV. The low susceptibility of HIV to DT combining CAB + RPV observed in this study advocates for the use of LAI CAB + RPV only among compliant individuals, with undetectable viremia (&#x0003c;50 copies/mL). In addition, it is worth noting that a careful assessment of NRTI- RAMs among ART-failing individuals may also help to understand the potential efficacy of DTG + 3TC dual therapies alongside that of LAI in these settings. These data also call for further investigation into viral reservoirs in people with virological success (&#x0003c;50 copies/mL), and even in ART-na&#x000ef;ve individuals.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01853"><title>5. Conclusions</title><p>In patients with virological failure, INSTI + 2nd-Gen-NNRTI combinations retain potential efficacy in less than half of the participants, and this is attributable to the very high rate of failure with the emergence of RAMs to 1st-Gen-NNRTI-based regimens. However, the introduction of these DTs must be systematically supported by HIV genotypic resistance testing. Considering the long exposure to 1st-Gen-NNRTIs, it would be prudent to reserve this therapeutic strategy (like the long-acting injectable RPV + CAB protocol) for adherent patients with no history of therapeutic failure to 1st-Gen-NNRTI (EFV or NVP) regimens. The general data clearly indicate that, without resistance testing, it is nearly impossible to use long-acting dual therapies in previously failing patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are thankful for the opportunity given by the &#x000ab;Chantal BIYA&#x000bb; International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) General direction to conduct research in virology laboratory. Extensive gratitude should go to the virology laboratory staff for their cooperation and technical support and for HIV-genotyping training during the study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.-H.G.A., E.N.J.S. and J.F.; Methodology, D.-H.G.A., G.B., E.N.J.S. and Y.B.; Software, A.C.K. and D.-H.G.A.; Validation, D.T., E.N.J.S. and A.D.N. Investigation, D.-H.G.A., G.B., E.N.J.S., C.A.C. and U.R.B.W.; Resources, D.M., C.-F.P., N.N., J.F. and A.N.; Data Curation, D.-H.G.A., U.R.B.W. and E.N.J.S.; Writing&#x02014;Original Draft Preparation, D.-H.G.A., A.C.K., E.N.J.S., Y.B. and J.F.; Writing&#x02014;Review and Editing, C.-F.P., J.F., D.-H.G.A., E.N.J.S. and Y.B.; Visualization, C.A.C., C.-F.P., M.M.S., F.C.-S., A.C., C.M., G.C. and V.C.; Supervision, D.M., C.-F.P., N.N., J.F. and A.N.; Project Administration, D.M., C.-F.P., N.N., J.F. and A.N.; Funding Acquisition, J.F., YG and A.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Review Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaound&#x000e9; I (Protocol N&#x000b0; 0043/UY1/FMSB/VDRC/DAASR/CSD, on 6 February 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived because the analysis was performed on an existing database of patients received for resistance testing at CIRCB. However, all the data were anonymized throughout the study process and we have strictly adhered to the recommendations from the ethics committee. </p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Nucleotide sequences for the HIV-1 Pol gene (<italic toggle="yes">RT-PR</italic> and <italic toggle="yes">integrase</italic> region) are available on GenBank under the following accession numbers: OQ985493&#x02013;OQ985499; OQ985501&#x02013;OQ985515; OQ985518; OQ985527; OQ985530&#x02013;OQ985557; OQ985570&#x02013;OQ985586; OQ985841&#x02013;OQ985844; OQ985904; OR259498&#x02013;OR259499; OR365155; OR259747&#x02013;OR259758; OR259547&#x02013;OR259558; OR259603&#x02013;OR259617; OR259672&#x02013;OR259683; OR259829; MN520217; OK086757; OR365153; MN520219; MW328641&#x02013;MW328663; MW328665&#x02013;MW328713; MZ044346&#x02013;MZ044400.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01853"><label>1.</label><element-citation publication-type="webpage"><article-title>UNAIDS Global HIV &#x00026; AIDS Statistics&#x02014;Fact Sheet</article-title><comment>Available online: <ext-link xlink:href="https://www.unaids.org/en/resources/fact-sheet" ext-link-type="uri">https://www.unaids.org/en/resources/fact-sheet</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-18">(accessed on 18 May 2024)</date-in-citation></element-citation></ref><ref id="B2-viruses-16-01853"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arts</surname><given-names>E.J.</given-names></name>
<name><surname>Hazuda</surname><given-names>D.J.</given-names></name>
</person-group><article-title>HIV-1 Antiretroviral Drug Therapy</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2012</year><volume>2</volume><fpage>a007161</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a007161</pub-id><pub-id pub-id-type="pmid">22474613</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01853"><label>3.</label><element-citation publication-type="webpage"><article-title>[Comit&#x000e9; National de Lutte Contre Le SIDA&#x02014;CNLS] [Cnls.Cm]</article-title><comment>Available online: <ext-link xlink:href="https://cnls.cm/site/fr/home-page-1" ext-link-type="uri">https://cnls.cm/site/fr/home-page-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-17">(accessed on 17 May 2024)</date-in-citation></element-citation></ref><ref id="B4-viruses-16-01853"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buell</surname><given-names>K.G.</given-names></name>
<name><surname>Chung</surname><given-names>C.</given-names></name>
<name><surname>Chaudhry</surname><given-names>Z.</given-names></name>
<name><surname>Puri</surname><given-names>A.</given-names></name>
<name><surname>Nawab</surname><given-names>K.</given-names></name>
<name><surname>Ravindran</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Lifelong Antiretroviral Therapy or HIV Cure: The Benefits for the Individual Patient</article-title><source>AIDS Care</source><year>2016</year><volume>28</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1080/09540121.2015.1074653</pub-id><pub-id pub-id-type="pmid">26357912</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01853"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gibas</surname><given-names>K.M.</given-names></name>
<name><surname>Kelly</surname><given-names>S.G.</given-names></name>
<name><surname>Arribas</surname><given-names>J.R.</given-names></name>
<name><surname>Cahn</surname><given-names>P.</given-names></name>
<name><surname>Orkin</surname><given-names>C.</given-names></name>
<name><surname>Daar</surname><given-names>E.S.</given-names></name>
<name><surname>Sax</surname><given-names>P.E.</given-names></name>
<name><surname>Taiwo</surname><given-names>B.O.</given-names></name>
</person-group><article-title>Two-Drug Regimens for HIV Treatment</article-title><source>Lancet HIV</source><year>2022</year><volume>9</volume><fpage>e868</fpage><lpage>e883</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(22)00249-1</pub-id><pub-id pub-id-type="pmid">36309038</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01853"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Ministry of Public Health of Cameroon</collab>
</person-group><source>National Guideline on the Prevention and Management of HIV in Cameroon</source><comment>Sant&#x000e9; Publique</comment><publisher-name>Ministry of Public Health of Cameroon</publisher-name><publisher-loc>Yaound&#x000e9;, Cameroon</publisher-loc><year>2021</year></element-citation></ref><ref id="B7-viruses-16-01853"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goicoechea</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Best</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
<name><surname>Jain</surname><given-names>S.</given-names></name>
<name><surname>Kemper</surname><given-names>C.</given-names></name>
<name><surname>Witt</surname><given-names>M.</given-names></name>
<name><surname>Diamond</surname><given-names>C.</given-names></name>
<name><surname>Haubrich</surname><given-names>R.</given-names></name>
<name><surname>Louie</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy</article-title><source>J. Infect. Dis.</source><year>2008</year><volume>197</volume><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1086/524061</pub-id><pub-id pub-id-type="pmid">18171292</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01853"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casado</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End</article-title><source>AIDS Rev.</source><year>2016</year><volume>18</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">27230467</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01853"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-N&#x000f3;voa</surname><given-names>S.</given-names></name>
<name><surname>Alvarez</surname><given-names>E.</given-names></name>
<name><surname>Labarga</surname><given-names>P.</given-names></name>
<name><surname>Soriano</surname><given-names>V.</given-names></name>
</person-group><article-title>Renal Toxicity Associated with Tenofovir Use</article-title><source>Expert Opin. Drug Saf.</source><year>2010</year><volume>9</volume><fpage>545</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1517/14740331003627458</pub-id><pub-id pub-id-type="pmid">20384533</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01853"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katz</surname><given-names>I.T.</given-names></name>
<name><surname>Ryu</surname><given-names>A.E.</given-names></name>
<name><surname>Onuegbu</surname><given-names>A.G.</given-names></name>
<name><surname>Psaros</surname><given-names>C.</given-names></name>
<name><surname>Weiser</surname><given-names>S.D.</given-names></name>
<name><surname>Bangsberg</surname><given-names>D.R.</given-names></name>
<name><surname>Tsai</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Impact of HIV-Related Stigma on Treatment Adherence: Systematic Review and Meta-Synthesis</article-title><source>J. Int. AIDS Soc.</source><year>2013</year><volume>16</volume><fpage>18640</fpage><pub-id pub-id-type="doi">10.7448/IAS.16.3.18640</pub-id><pub-id pub-id-type="pmid">24242258</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01853"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chawla</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Patton</surname><given-names>C.</given-names></name>
<name><surname>Murray</surname><given-names>M.</given-names></name>
<name><surname>Punekar</surname><given-names>Y.</given-names></name>
<name><surname>de Ruiter</surname><given-names>A.</given-names></name>
<name><surname>Steinhart</surname><given-names>C.</given-names></name>
</person-group><article-title>A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population</article-title><source>Infect. Dis. Ther.</source><year>2018</year><volume>7</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1007/s40121-018-0201-6</pub-id><pub-id pub-id-type="pmid">29761330</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01853"><label>12.</label><element-citation publication-type="gov"><article-title>FDA-Approved HIV Medicines|NIH</article-title><comment>Available online: <ext-link xlink:href="https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines" ext-link-type="uri">https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-06">(accessed on 6 May 2024)</date-in-citation></element-citation></ref><ref id="B13-viruses-16-01853"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Men&#x000e9;ndez-Arias</surname><given-names>L.</given-names></name>
<name><surname>Betancor</surname><given-names>G.</given-names></name>
<name><surname>Matamoros</surname><given-names>T.</given-names></name>
</person-group><article-title>HIV-1 Reverse Transcriptase Connection Subdomain Mutations Involved in Resistance to Approved Non-Nucleoside Inhibitors</article-title><source>Antivir. Res.</source><year>2011</year><volume>92</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.08.020</pub-id><pub-id pub-id-type="pmid">21896288</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01853"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>S.J.</given-names></name>
<name><surname>Pauly</surname><given-names>G.T.</given-names></name>
<name><surname>Akram</surname><given-names>A.</given-names></name>
<name><surname>Melody</surname><given-names>K.</given-names></name>
<name><surname>Ambrose</surname><given-names>Z.</given-names></name>
<name><surname>Schneider</surname><given-names>J.P.</given-names></name>
<name><surname>Hughes</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Rilpivirine and Doravirine Have Complementary Efficacies against NNRTI-Resistant HIV-1 Mutants</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2016</year><volume>72</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001031</pub-id><pub-id pub-id-type="pmid">27124362</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01853"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havens</surname><given-names>J.P.</given-names></name>
<name><surname>Podany</surname><given-names>A.T.</given-names></name>
<name><surname>Scarsi</surname><given-names>K.K.</given-names></name>
<name><surname>Fletcher</surname><given-names>C.V.</given-names></name>
</person-group><article-title>Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review</article-title><source>Clin. Pharmacokinet.</source><year>2020</year><volume>59</volume><fpage>137</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1007/s40262-019-00830-9</pub-id><pub-id pub-id-type="pmid">31679131</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01853"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scarsi</surname><given-names>K.K.</given-names></name>
<name><surname>Havens</surname><given-names>J.P.</given-names></name>
<name><surname>Podany</surname><given-names>A.T.</given-names></name>
<name><surname>Avedissian</surname><given-names>S.N.</given-names></name>
<name><surname>Fletcher</surname><given-names>C.V.</given-names></name>
</person-group><article-title>HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety</article-title><source>Drugs</source><year>2020</year><volume>80</volume><fpage>1649</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01379-9</pub-id><pub-id pub-id-type="pmid">32860583</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01853"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katlama</surname><given-names>C.</given-names></name>
<name><surname>Assoumou</surname><given-names>L.</given-names></name>
<name><surname>Valantin</surname><given-names>M.-A.</given-names></name>
<name><surname>Souli&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Martinez</surname><given-names>E.</given-names></name>
<name><surname>B&#x000e9;niguel</surname><given-names>L.</given-names></name>
<name><surname>Bouchaud</surname><given-names>O.</given-names></name>
<name><surname>Raffi</surname><given-names>F.</given-names></name>
<name><surname>Molina</surname><given-names>J.-M.</given-names></name>
<name><surname>Fellahi</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Dual Therapy Combining Raltegravir with Etravirine Maintains a High Level of Viral Suppression over 96 Weeks in Long-Term Experienced HIV-Infected Individuals over 45 Years on a PI-Based Regimen: Results from the Phase II ANRS 163 ETRAL Study</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>2742</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz224</pub-id><pub-id pub-id-type="pmid">31269208</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01853"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soulie</surname><given-names>C.</given-names></name>
<name><surname>Assoumou</surname><given-names>L.</given-names></name>
<name><surname>Abdi</surname><given-names>B.</given-names></name>
<name><surname>Sayon</surname><given-names>S.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.</given-names></name>
<name><surname>Valantin</surname><given-names>M.-A.</given-names></name>
<name><surname>Beniguel</surname><given-names>L.</given-names></name>
<name><surname>Ferre</surname><given-names>V.</given-names></name>
<name><surname>Alloui</surname><given-names>C.</given-names></name>
<name><surname>Montes</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Characterization of Viral Rebounds on Dual Etravirine/Raltegravir Maintenance Therapy (ANRS-163 ETRAL Trial)</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>1943</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa090</pub-id><pub-id pub-id-type="pmid">32259255</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01853"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llibre</surname><given-names>J.M.</given-names></name>
<name><surname>Hung</surname><given-names>C.-C.</given-names></name>
<name><surname>Brinson</surname><given-names>C.</given-names></name>
<name><surname>Castelli</surname><given-names>F.</given-names></name>
<name><surname>Girard</surname><given-names>P.-M.</given-names></name>
<name><surname>Kahl</surname><given-names>L.P.</given-names></name>
<name><surname>Blair</surname><given-names>E.A.</given-names></name>
<name><surname>Angelis</surname><given-names>K.</given-names></name>
<name><surname>Wynne</surname><given-names>B.</given-names></name>
<name><surname>Vandermeulen</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33095-7</pub-id><pub-id pub-id-type="pmid">29310899</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01853"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McComsey</surname><given-names>G.A.</given-names></name>
<name><surname>Lupo</surname><given-names>S.</given-names></name>
<name><surname>Parks</surname><given-names>D.</given-names></name>
<name><surname>Poggio</surname><given-names>M.C.</given-names></name>
<name><surname>De Wet</surname><given-names>J.</given-names></name>
<name><surname>Kahl</surname><given-names>L.P.</given-names></name>
<name><surname>Angelis</surname><given-names>K.</given-names></name>
<name><surname>Wynne</surname><given-names>B.</given-names></name>
<name><surname>Vandermeulen</surname><given-names>K.</given-names></name>
<name><surname>Gartland</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Switch from Tenofovir Disoproxil Fumarate Combination to Dolutegravir with Rilpivirine Improves Parameters of Bone Health</article-title><source>AIDS</source><year>2018</year><volume>32</volume><fpage>477</fpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001725</pub-id><pub-id pub-id-type="pmid">29239893</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01853"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swindells</surname><given-names>S.</given-names></name>
<name><surname>Lutz</surname><given-names>T.</given-names></name>
<name><surname>Van Zyl</surname><given-names>L.</given-names></name>
<name><surname>Porteiro</surname><given-names>N.</given-names></name>
<name><surname>Stoll</surname><given-names>M.</given-names></name>
<name><surname>Mitha</surname><given-names>E.</given-names></name>
<name><surname>Shon</surname><given-names>A.</given-names></name>
<name><surname>Benn</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>J.O.</given-names></name>
<name><surname>Harrington</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group><article-title>Week 96 Extension Results of a Phase 3 Study Evaluating Long-Acting Cabotegravir with Rilpivirine for HIV-1 Treatment</article-title><source>AIDS</source><year>2022</year><volume>36</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003025</pub-id><pub-id pub-id-type="pmid">34261093</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01853"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orkin</surname><given-names>C.</given-names></name>
<name><surname>Arasteh</surname><given-names>K.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Mora</surname><given-names>M.G.</given-names></name>
<name><surname>Pokrovsky</surname><given-names>V.</given-names></name>
<name><surname>Overton</surname><given-names>E.T.</given-names></name>
<name><surname>Girard</surname><given-names>P.-M.</given-names></name>
<name><surname>Oka</surname><given-names>S.</given-names></name>
<name><surname>Walmsley</surname><given-names>S.</given-names></name>
<name><surname>Bettacchi</surname><given-names>C.</given-names></name>
<name><surname>Brinson</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1124</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1909512</pub-id><pub-id pub-id-type="pmid">32130806</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01853"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barabona</surname><given-names>G.</given-names></name>
<name><surname>Mahiti</surname><given-names>M.</given-names></name>
<name><surname>Masoud</surname><given-names>S.</given-names></name>
<name><surname>Mbelele</surname><given-names>P.</given-names></name>
<name><surname>Mgunya</surname><given-names>A.S.</given-names></name>
<name><surname>Minja</surname><given-names>L.</given-names></name>
<name><surname>Sunguya</surname><given-names>B.</given-names></name>
<name><surname>Shigemi</surname><given-names>U.</given-names></name>
<name><surname>Matsuda</surname><given-names>M.</given-names></name>
<name><surname>Hachiya</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Pre-Treatment and Acquired HIV Drug Resistance in Dar Es Salaam, Tanzania in the Era of Tenofovir and Routine Viral Load Monitoring</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>3016</fpage><lpage>3020</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz272</pub-id><pub-id pub-id-type="pmid">31273377</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01853"><label>24.</label><element-citation publication-type="webpage"><article-title>HIV Drug Resistance Report 2021</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications-detail-redirect/9789240038608" ext-link-type="uri">https://www.who.int/publications-detail-redirect/9789240038608</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-10">(accessed on 10 May 2024)</date-in-citation></element-citation></ref><ref id="B25-viruses-16-01853"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fokam</surname><given-names>J.</given-names></name>
<name><surname>Chenwi</surname><given-names>C.A.</given-names></name>
<name><surname>Takou</surname><given-names>D.</given-names></name>
<name><surname>Santoro</surname><given-names>M.M.</given-names></name>
<name><surname>Tala</surname><given-names>V.</given-names></name>
<name><surname>Teto</surname><given-names>G.</given-names></name>
<name><surname>Beloumou</surname><given-names>G.</given-names></name>
<name><surname>Semengue</surname><given-names>E.N.J.</given-names></name>
<name><surname>Dambaya</surname><given-names>B.</given-names></name>
<name><surname>Djupsa</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1683</elocation-id><pub-id pub-id-type="doi">10.3390/v15081683</pub-id><pub-id pub-id-type="pmid">37632026</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01853"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fokam</surname><given-names>J.</given-names></name>
<name><surname>Chenwi</surname><given-names>C.A.</given-names></name>
<name><surname>Tala</surname><given-names>V.</given-names></name>
<name><surname>Takou</surname><given-names>D.</given-names></name>
<name><surname>Santoro</surname><given-names>M.M.</given-names></name>
<name><surname>Teto</surname><given-names>G.</given-names></name>
<name><surname>Dambaya</surname><given-names>B.</given-names></name>
<name><surname>Anubodem</surname><given-names>F.</given-names></name>
<name><surname>Semengue</surname><given-names>E.N.J.</given-names></name>
<name><surname>Beloumou</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1458</elocation-id><pub-id pub-id-type="doi">10.3390/v15071458</pub-id><pub-id pub-id-type="pmid">37515146</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01853"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Courtney</surname><given-names>C.R.</given-names></name>
<name><surname>Agyingi</surname><given-names>L.</given-names></name>
<name><surname>Fokou</surname><given-names>A.</given-names></name>
<name><surname>Christie</surname><given-names>S.</given-names></name>
<name><surname>Asaah</surname><given-names>B.</given-names></name>
<name><surname>Meli</surname><given-names>J.</given-names></name>
<name><surname>Ngai</surname><given-names>J.</given-names></name>
<name><surname>Hewlett</surname><given-names>I.</given-names></name>
<name><surname>Nyambi</surname><given-names>P.N.</given-names></name>
</person-group><article-title>Monitoring HIV-1 Group M Subtypes in Yaound&#x000e9;, Cameroon Reveals Broad Genetic Diversity and a Novel CRF02_AG/F2 Infection</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2016</year><volume>32</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0286</pub-id><pub-id pub-id-type="pmid">26681241</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01853"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fokam</surname><given-names>J.</given-names></name>
<name><surname>Salpini</surname><given-names>R.</given-names></name>
<name><surname>Santoro</surname><given-names>M.M.</given-names></name>
<name><surname>Cento</surname><given-names>V.</given-names></name>
<name><surname>D&#x02019;Arrigo</surname><given-names>R.</given-names></name>
<name><surname>Gori</surname><given-names>C.</given-names></name>
<name><surname>Perno</surname><given-names>C.F.</given-names></name>
<name><surname>Colizzi</surname><given-names>V.</given-names></name>
<name><surname>Nanfack</surname><given-names>A.</given-names></name>
<name><surname>Gwom</surname><given-names>L.C.</given-names></name>
<etal/>
</person-group><article-title>Performance Evaluation of an In-House Human Immunodeficiency Virus Type-1 Protease-Reverse Transcriptase Genotyping Assay in Cameroon</article-title><source>Arch. Virol.</source><year>2011</year><volume>156</volume><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1007/s00705-011-0982-3</pub-id><pub-id pub-id-type="pmid">21465085</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01853"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fokam</surname><given-names>J.</given-names></name>
<name><surname>Ngoufack Jagni Semengue</surname><given-names>E.</given-names></name>
<name><surname>Armenia</surname><given-names>D.</given-names></name>
<name><surname>Takou</surname><given-names>D.</given-names></name>
<name><surname>Dambaya</surname><given-names>B.</given-names></name>
<name><surname>Teto</surname><given-names>G.</given-names></name>
<name><surname>Chenwi</surname><given-names>C.A.</given-names></name>
<name><surname>Nka</surname><given-names>A.D.</given-names></name>
<name><surname>Beloumou</surname><given-names>G.A.</given-names></name>
<name><surname>Ndjeyep</surname><given-names>S.C.D.</given-names></name>
<etal/>
</person-group><article-title>High Performance of Integrase Genotyping on Diverse HIV-1 Clades Circulating in Cameroon: Toward a Successful Transition to Dolutegravir-Based Regimens in Low and Middle-Income Countries</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2022</year><volume>102</volume><elocation-id>115574</elocation-id><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2021.115574</pub-id><pub-id pub-id-type="pmid">34864527</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01853"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>J.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Mankaryous</surname><given-names>N.</given-names></name>
<name><surname>Tadros</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents</article-title><source>Ann. Pharmacother.</source><year>2010</year><volume>44</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1345/aph.1M359</pub-id><pub-id pub-id-type="pmid">19996323</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01853"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>del Mar Gutierrez</surname><given-names>M.</given-names></name>
<name><surname>Mateo</surname><given-names>M.G.</given-names></name>
<name><surname>Vidal</surname><given-names>F.</given-names></name>
<name><surname>Domingo</surname><given-names>P.</given-names></name>
</person-group><article-title>Drug Safety Profile of Integrase Strand Transfer Inhibitors</article-title><source>Expert Opin. Drug Saf.</source><year>2014</year><volume>13</volume><fpage>431</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1517/14740338.2014.897327</pub-id><pub-id pub-id-type="pmid">24597519</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01853"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>S.J.</given-names></name>
<name><surname>Zhao</surname><given-names>X.Z.</given-names></name>
<name><surname>Passos</surname><given-names>D.O.</given-names></name>
<name><surname>Lyumkis</surname><given-names>D.</given-names></name>
<name><surname>Burke</surname><given-names>T.R.</given-names></name>
<name><surname>Hughes</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>205</elocation-id><pub-id pub-id-type="doi">10.3390/v13020205</pub-id><pub-id pub-id-type="pmid">33572956</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01853"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Himmel</surname><given-names>D.M.</given-names></name>
<name><surname>Arnold</surname><given-names>E.</given-names></name>
</person-group><article-title>Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.3390/ph13060122</pub-id><pub-id pub-id-type="pmid">32545407</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01853"><label>34.</label><element-citation publication-type="webpage"><article-title>NNRTI Resistance Notes&#x02014;HIV Drug Resistance Database</article-title><comment>Available online: <ext-link xlink:href="https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/" ext-link-type="uri">https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-30">(accessed on 30 August 2024)</date-in-citation></element-citation></ref><ref id="B35-viruses-16-01853"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndashimye</surname><given-names>E.</given-names></name>
<name><surname>Avino</surname><given-names>M.</given-names></name>
<name><surname>Olabode</surname><given-names>A.S.</given-names></name>
<name><surname>Poon</surname><given-names>A.F.Y.</given-names></name>
<name><surname>Gibson</surname><given-names>R.M.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Meadows</surname><given-names>A.</given-names></name>
<name><surname>Tan</surname><given-names>C.</given-names></name>
<name><surname>Reyes</surname><given-names>P.S.</given-names></name>
<name><surname>Kityo</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group><article-title>Accumulation of Integrase Strand Transfer Inhibitor Resistance Mutations Confers High-Level Resistance to Dolutegravir in Non-B Subtype HIV-1 Strains from Patients Failing Raltegravir in Uganda</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>3525</fpage><lpage>3533</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa355</pub-id><pub-id pub-id-type="pmid">32853364</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01853"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abram</surname><given-names>M.E.</given-names></name>
<name><surname>Ram</surname><given-names>R.R.</given-names></name>
<name><surname>Margot</surname><given-names>N.A.</given-names></name>
<name><surname>Barnes</surname><given-names>T.L.</given-names></name>
<name><surname>White</surname><given-names>K.L.</given-names></name>
<name><surname>Callebaut</surname><given-names>C.</given-names></name>
<name><surname>Miller</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Lack of Impact of Pre-Existing T97A HIV-1 Integrase Mutation on Integrase Strand Transfer Inhibitor Resistance and Treatment Outcome</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0172206</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0172206</pub-id><pub-id pub-id-type="pmid">28212411</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01853"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Bouzidi</surname><given-names>K.</given-names></name>
<name><surname>Kemp</surname><given-names>S.A.</given-names></name>
<name><surname>Datir</surname><given-names>R.P.</given-names></name>
<name><surname>Murtala-Ibrahim</surname><given-names>F.</given-names></name>
<name><surname>Aliyu</surname><given-names>A.</given-names></name>
<name><surname>Kwaghe</surname><given-names>V.</given-names></name>
<name><surname>Frampton</surname><given-names>D.</given-names></name>
<name><surname>Roy</surname><given-names>S.</given-names></name>
<name><surname>Breuer</surname><given-names>J.</given-names></name>
<name><surname>Sabin</surname><given-names>C.A.</given-names></name>
<etal/>
</person-group><article-title>High Prevalence of Integrase Mutation L74I in West African HIV-1 Subtypes Prior to Integrase Inhibitor Treatment</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>1575</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa033</pub-id><pub-id pub-id-type="pmid">32105319</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01853"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cutrell</surname><given-names>A.G.</given-names></name>
<name><surname>Schapiro</surname><given-names>J.M.</given-names></name>
<name><surname>Perno</surname><given-names>C.F.</given-names></name>
<name><surname>Kuritzkes</surname><given-names>D.R.</given-names></name>
<name><surname>Quercia</surname><given-names>R.</given-names></name>
<name><surname>Patel</surname><given-names>P.</given-names></name>
<name><surname>Polli</surname><given-names>J.W.</given-names></name>
<name><surname>Dorey</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Exploring Predictors of HIV-1 Virologic Failure to Long-Acting Cabotegravir and Rilpivirine: A Multivariable Analysis</article-title><source>AIDS</source><year>2021</year><volume>35</volume><fpage>1333</fpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002883</pub-id><pub-id pub-id-type="pmid">33730748</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01853"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>M.</given-names></name>
<name><surname>Ibanescu</surname><given-names>R.-I.</given-names></name>
<name><surname>Anstett</surname><given-names>K.</given-names></name>
<name><surname>M&#x000e9;spl&#x000e8;de</surname><given-names>T.</given-names></name>
<name><surname>Routy</surname><given-names>J.-P.</given-names></name>
<name><surname>Robbins</surname><given-names>M.A.</given-names></name>
<name><surname>Brenner</surname><given-names>B.G.</given-names></name>
<name><surname>Legault</surname><given-names>M.</given-names></name>
<name><surname>Baril</surname><given-names>J.-G.</given-names></name>
<name><surname>Charest</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Selective Resistance Profiles Emerging in Patient-Derived Clinical Isolates with Cabotegravir, Bictegravir, Dolutegravir, and Elvitegravir</article-title><source>Retrovirology</source><year>2018</year><volume>15</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s12977-018-0440-3</pub-id><pub-id pub-id-type="pmid">30119633</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01853"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saravanan</surname><given-names>S.</given-names></name>
<name><surname>Kausalya</surname><given-names>B.</given-names></name>
<name><surname>Gomathi</surname><given-names>S.</given-names></name>
<name><surname>Sivamalar</surname><given-names>S.</given-names></name>
<name><surname>Pachamuthu</surname><given-names>B.</given-names></name>
<name><surname>Selvamuthu</surname><given-names>P.</given-names></name>
<name><surname>Pradeep</surname><given-names>A.</given-names></name>
<name><surname>Sunil</surname><given-names>S.</given-names></name>
<name><surname>Mothi</surname><given-names>S.N.</given-names></name>
<name><surname>Smith</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2017</year><volume>33</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1089/aid.2016.0133</pub-id><pub-id pub-id-type="pmid">27869478</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01853"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henerico</surname><given-names>S.</given-names></name>
<name><surname>Mikasi</surname><given-names>S.G.</given-names></name>
<name><surname>Kalluvya</surname><given-names>S.E.</given-names></name>
<name><surname>Brauner</surname><given-names>J.M.</given-names></name>
<name><surname>Abdul</surname><given-names>S.</given-names></name>
<name><surname>Lyimo</surname><given-names>E.</given-names></name>
<name><surname>Desderius</surname><given-names>B.</given-names></name>
<name><surname>Korn</surname><given-names>K.</given-names></name>
<name><surname>van Zyl</surname><given-names>G.</given-names></name>
<name><surname>Jacobs</surname><given-names>G.B.</given-names></name>
<etal/>
</person-group><article-title>Prevalence and Patterns of HIV Drug Resistance in Patients with Suspected Virological Failure in North-Western Tanzania</article-title><source>J. Antimicrob. Chemother.</source><year>2022</year><volume>77</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab406</pub-id><pub-id pub-id-type="pmid">35107140</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01853"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clevenbergh</surname><given-names>P.</given-names></name>
<name><surname>Cua</surname><given-names>E.</given-names></name>
<name><surname>Dam</surname><given-names>E.</given-names></name>
<name><surname>Durant</surname><given-names>J.</given-names></name>
<name><surname>Schmit</surname><given-names>J.C.</given-names></name>
<name><surname>Boulme</surname><given-names>R.</given-names></name>
<name><surname>Cottalorda</surname><given-names>J.</given-names></name>
<name><surname>Beyou</surname><given-names>A.</given-names></name>
<name><surname>Schapiro</surname><given-names>J.M.</given-names></name>
<name><surname>Clavel</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Prevalence of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance-Associated Mutations and Polymorphisms in NNRTI-Na&#x000ef;ve HIV-Infected Patients</article-title><source>HIV Clin. Trials</source><year>2002</year><volume>3</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1310/5H0R-UDC8-8RR7-XEMJ</pub-id><pub-id pub-id-type="pmid">11819184</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01853"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kityo</surname><given-names>C.</given-names></name>
<name><surname>Mambule</surname><given-names>I.K.</given-names></name>
<name><surname>Musaazi</surname><given-names>J.</given-names></name>
<name><surname>Sokhela</surname><given-names>S.</given-names></name>
<name><surname>Mugerwa</surname><given-names>H.</given-names></name>
<name><surname>Ategeka</surname><given-names>G.</given-names></name>
<name><surname>Cresswell</surname><given-names>F.</given-names></name>
<name><surname>Siika</surname><given-names>A.</given-names></name>
<name><surname>Kosgei</surname><given-names>J.</given-names></name>
<name><surname>Shah</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Switch to Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adults with HIV in Africa (CARES): Week 48 Results from a Randomised, Multicentre, Open-Label, Non-Inferiority Trial</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>1083</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00289-5</pub-id><pub-id pub-id-type="pmid">38821073</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01853"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramalingam</surname><given-names>V.V.</given-names></name>
<name><surname>Demosthenes</surname><given-names>J.P.</given-names></name>
<name><surname>Ghale</surname><given-names>B.C.</given-names></name>
<name><surname>Rupali</surname><given-names>P.</given-names></name>
<name><surname>Varghese</surname><given-names>G.M.</given-names></name>
<name><surname>Abraham</surname><given-names>O.C.</given-names></name>
<name><surname>Kannangai</surname><given-names>R.</given-names></name>
</person-group><article-title>Frequency of Cross-Resistance to Rilpivirine and Etravirine among HIV-1 Subtype C Infected Individuals Failing Nevirapine/Efavirenz Based ART Regimen</article-title><source>Infect. Dis.</source><year>2019</year><volume>51</volume><fpage>71</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1080/23744235.2018.1510182</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01853-f001"><label>Figure 1</label><caption><p>HIV-1 subtype distribution in the study population.</p></caption><graphic xlink:href="viruses-16-01853-g001" position="float"/></fig><fig position="float" id="viruses-16-01853-f002"><label>Figure 2</label><caption><p>Predictive efficacy of potential DT combining INSTIs and 2nd-Gen-NNRTs. (<bold>a</bold>) Frequency of patients who are susceptible to RPV + INSTIs; (<bold>b</bold>) Frequency of patients who are susceptible to DOR + INSTIs; (<bold>c</bold>) Frequency of patients who are susceptible to ETR + INSTIs. The error bars represent the 95% confidence interval.</p></caption><graphic xlink:href="viruses-16-01853-g002" position="float"/></fig><fig position="float" id="viruses-16-01853-f003"><label>Figure 3</label><caption><p>Determinants of the predictive efficacy of a potential dual-therapy-based second-generation NNRTIs + INSTIs. Legend: (<bold>A</bold>) Predictive efficacy of CAB + RPV according to previous treatment failure history; (<bold>B</bold>) Predictive efficacy of CAB + RPV according to the presence of RAMs; (<bold>C</bold>) Predictive efficacy of CAB + DOR according to previous treatment failure history; (<bold>D</bold>) Predictive efficacy of CAB + DOR according to the presence of RAMs; (<bold>E</bold>) Predictive efficacy of CAB + ETR according to previous treatment failure history; (<bold>F</bold>) Predictive efficacy of CAB + ETR according to the presence of RAMs.</p></caption><graphic xlink:href="viruses-16-01853-g003" position="float"/></fig><table-wrap position="float" id="viruses-16-01853-t001"><object-id pub-id-type="pii">viruses-16-01853-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Categories or Medians [IQR]</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall (<italic toggle="yes">N</italic> = 130)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" rowspan="1" colspan="1">53 (40.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" rowspan="1" colspan="1">77 (59.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="middle" rowspan="1" colspan="1">Median (IQR)</td><td align="left" valign="middle" rowspan="1" colspan="1">38 (27&#x02013;46)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age groups (years), n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">Adolescents</td><td align="left" valign="middle" rowspan="1" colspan="1">21 (16.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Adults</td><td align="left" valign="middle" rowspan="1" colspan="1">109 (83.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Viremia (at the time of failure, copies/mL)</td><td align="left" valign="middle" rowspan="1" colspan="1">Median (IQR)</td><td align="left" valign="middle" rowspan="1" colspan="1">35,078 (5746&#x02013;178,655)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART duration (months)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median (IQR)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84 (42&#x02013;144)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NNRTI plus 2NRTIs regimens, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">ABC + 3TC + EFV</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">AZT + 3TC + EFV</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">TDF + 3TC + EFV</td><td align="left" valign="middle" rowspan="1" colspan="1">34 (26.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">AZT + 3TC + NVP</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (6.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF + 3TC + NVP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (3.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PI plus 2NRTIs regimens, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">ABC + 3TC + LPV/r</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (3.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">ABC + 3TC + ATV/r</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (7.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">AZT + 3TC + LPV/r</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">AZT + 3TC + ATVr</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">TDF + 3TC + LPV/r</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF + 3TC + ATV/r</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (30.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INSTI plus 2NRTIs regimens, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">ABC + 3TC + DTG</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF + 3TC + DTG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (6.9)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: IQR: Interquartile range; 3TC: Lamivudine; ABC: Abacavir; ATV/r: Ritonavir-boosted Atazanavir; AZT: Zidovudine; DTG: Dolutegravir; EFV: Efavirenz; NVP: Nevirapine; LPV/r: Ritonavir-boosted Lopinavir; NNRTI: Non-nucleotide reverse transcriptase inhibitors; NRTI: Nucleotide reverse transcriptase inhibitors; TDF: Tenofovir; PI: Protease inhibitor; INSTI: Integrase strand transfer inhibitor; ART: Antiretroviral therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01853-t002"><object-id pub-id-type="pii">viruses-16-01853-t002_Table 2</object-id><label>Table 2</label><caption><p>Distribution of INSTIs and 2nd-Gen-NNRTI RAMs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Class</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prevalence n (%)</th></tr></thead><tbody><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">INSTIs *</td><td align="left" valign="middle" rowspan="1" colspan="1">E138K</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">G140A</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Q148R</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R263K</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S147G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td rowspan="12" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2nd-Gen-NNRTIs</td><td align="left" valign="middle" rowspan="1" colspan="1">A98G</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (15.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">E138AGKQ</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (9.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">G190ASE</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (17.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L234I</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L100I</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (3.0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">K101PE</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (10.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">V179L</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (13.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Y181C</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (32.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Y188CL</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H221Y</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (6.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">F227FL</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (6.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M230L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (3.0)</td></tr></tbody></table><table-wrap-foot><fn><p>* The INSTI mutations were found in two participants.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01853-t003"><object-id pub-id-type="pii">viruses-16-01853-t003_Table 3</object-id><label>Table 3</label><caption><p>Potential efficacies of INSTIs and 2nd-Gen-NNRTIs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Class</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intermediate or High Resistance<break/>n (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Susceptible<break/>n (%)</th></tr></thead><tbody><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2nd-Gen-NNRTIs</td><td align="left" valign="middle" rowspan="1" colspan="1">ETR</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (56.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (43.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOR</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (58.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (41.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80 (61.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (38.5)</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">INSTIs</td><td align="left" valign="middle" rowspan="1" colspan="1">BIC</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (97.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAB</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">125 (96.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DTG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (2.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127 (97.7)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: ETR: Etravirine; DOR: Doravirine; RPV: Rilpivirine; BIC: Bictegravir; DTG: Dolutegravir; CAB: Cabotegravir; NVP: Nevirapine; LPV/r: Ritonavir-boosted Lopinavir; 2nd-Gen-NNRTI: Second-generation non-nucleotide reverse transcriptase inhibitors; INSTIs: Integrase strand transfer inhibitors.</p></fn></table-wrap-foot></table-wrap></floats-group></article>